| 447 | 1 | 224 |
| 下载次数 | 被引频次 | 阅读次数 |
急性髓系白血病(AML)是一种异质性血液系统恶性肿瘤。近年来，随着各种生物学技术，如流式细胞术、分子生物学、质谱等的飞速发展及应用，人们对于AML的发病机制有了更深入的认识，世界卫生组织多次更新了AML的疾病诊断分类，欧洲白血病网也修订了AML的遗传危险度分层建议。与此同时，针对AML患者治疗后可检测残留病的监测、治疗方案的分层设计及分子靶向药物与免疫治疗的应用也取得了长足的进步，AML进入了更加精准的诊治时代。
Abstract：Acute myeloid leukemia(AML) is a heterogeneous hematological malignancy. In recent years, with the rapid development and application of various biological techniques, such as flow cytometry, molecular biology and mass spectrometry, people have a deeper understanding of the pathogenesis of AML. The World Health Organization has updated the diagnostic classification of AML several times, and the European Leukemia Network has revised the recommendations for genetic risk stratification of AML. At the same time, great progress has been made in the monitoring of measurable residual disease after treatment, the hierarchical design of treatment regimens, and the application of molecular targeted drugs and immunotherapy. AML has entered the era of more precise diagnosis and treatment.
[1] D?hner H,Wei A H,Appelbaum F R,et al.Diagnosis and management of AML in adults:2022 recommendations from an international expert panel on behalf of the ELN[J].Blood,2022,140(12):1345-1377.
[2] NCCN临床实践指南：急性髓性白血病(2024.V2)[Z].
[3] Khoury J D,Solary E,Abla O,et al.The 5th edition of the World Health Organization classification of haematolymphoid tumours:myeloid and histiocytic/dendritic neoplasms[J].Leukemia,2022,36(7):1703-1719.
[4] Arber D A,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[5] D?hner H,Estey E,Grimwade D,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel[J].Blood,2017,129(4):424-447.
[6] 中华医学会血液学分会白血病淋巴瘤学组.中国成人急性髓系白血病(非急性早幼粒细胞白血病)诊疗指南(2021年版)[J].中华血液学杂志，2021,42(8):617-623.
[7] 中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)[J].中华血液学杂志，2023,44(9):705-712.
[8] Slovak M L,Kopecky K J,Cassileth P A,et al.Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Group/Eastern Cooperative Oncology Group Study[J].Blood,2000,96(13):4075-4083.
[9] 中华医学会血液学分会实验诊断学组.急性髓系白血病微小残留病检测与临床解读中国专家共识(2021年版)[J].中华血液学杂志，2021,42(11):889-897.
[10] Appelbaum F R,Gundacker H,Head D R,et al.Age and acute myeloid leukemia[J].Blood,2006,107(9):3481-3485.
[11] Fernandez H F,Sun Z X,Yao X P,et al.Anthracycline dose intensification in acute myeloid leukemia[J].N Engl J Med,2009,361(13):1249-1259.
[12] Ohtake S,Miyawaki S,Fujita H,et al.Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia:the JALSG AML201 Study[J].Blood,2011,117(8):2358-2365.
[13] Stone R M,Mandrekar S J,Sanford B L,et al.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation[J].N Engl J Med,2017,377(5):454-464.
[14] Erba H P,Montesinos P,Kim H J,et al.Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2023,401(10388):1571-1583.
[15] Stein E M,DiNardo C D,Fathi A T,et al.Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML:a phase 1 study[J].Blood,2021,137(13):1792-1803.
[16] Mayer R J,Davis R B,Schiffer C A,et al.Intensive postremission chemotherapy in adults with acute myeloid leukemia.Cancer and Leukemia Group B[J].N Engl J Med,1994,331(14):896-903.
[17] Bloomfield C D,Lawrence D,Byrd J C,et al.Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype[J].Cancer Res,1998,58(18):4173-4179.
[18] Koreth J,Schlenk R,Kopecky K J,et al.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission:systematic review and meta-analysis of prospective clinical trials[J].JAMA,2009,301(22):2349-2361.
[19] Burnett A K,Russell N H,Hills R K,et al.Optimization of chemotherapy for younger patients with acute myeloid leukemia:results of the medical research council AML15 trial[J].J Clin Oncol,2013,31(27):3360-3368.
[20] Huls G,Chitu D A,Havelange V,et al.Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients[J].Blood,2019,133(13):1457-1464.
[21] Wei A H,D?hner H,Pocock C,et al.Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission[J].N Engl J Med,2020,383(26):2526-2537.
[22] Burchert A,Bug G,Fritz L V,et al.Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)[J].J Clin Oncol,2020,38(26):2993-3002.
[23] Xuan L,Wang Y,Huang F,et al.Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation:an open-label,multicentre,randomised phase 3 trial[J].Lancet Oncol,2020,21(9):1201-1212.
[24] DiNardo C D,Jonas B A,Pullarkat V,et al.Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J].N Engl J Med,2020,383(7):617-629.
[25] DiNardo C D,Pratz K,Pullarkat V,et al.Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia[J].Blood,2019,133(1):7-17.
[26] Dombret H,Seymour J F,Butrym A,et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts[J].Blood,2015,126(3):291-299.
[27] Fenaux P,Mufti G J,Hellstr?m-Lindberg E,et al.Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia[J].J Clin Oncol,2010,28(4):562-569.
[28] Kantarjian H M,Thomas X G,Dmoszynska A,et al.Multicenter,randomized,open-label,phaseⅢtrial of decitabine versus patient choice,with physician advice,of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J].J Clin Oncol,2012,30(21):2670-2677.
[29] Qian S X,Li J Y,Tian T,et al.Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia[J].Leuk Res,2007,31(10):1383-1388.
[30] Li J Y,Chen Y Y,Zhu Y,et al.Efficacy and safety of decitabine in combination with G-CSF,low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia[J].Oncotarget,2015,6(8):6448-6458.
[31] Montesinos P,Recher C,Vives S,et al.Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia[J].N Engl J Med,2022,386(16):1519-1531.
[32] Daver N,Perl A E,Maly J,et al.Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia[J].J Clin Oncol,2022,40(35):4048-4059.
[33] Wang E S,Montesinos P,Minden M D,et al.Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy[J].Blood,2022,140(17):1845-1857.
[34] Cornelissen J J,Blaise D.Hematopoietic stem cell transplantation for patients with AML in first complete remission[J].Blood,2016,127(1):62-70.
[35] Kekre N,Kim H T,Thanarajasingam G,et al.Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation[J].Haematologica,2015,100(9):1222-1227.
[36] Schmid C,Labopin M,Schaap N,et al.Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia[J].Bone Marrow Transplant,2022,57(2):215-223.
[37] Perl A E,Larson R A,Podoltsev N A,et al.Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial[J].Blood,2022,139(23):3366-3375.
[38] Perl A E,Martinelli G,Cortes J E,et al.Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML[J].N Engl J Med,2019,381(18):1728-1740.
[39] D?hner H,Weber D,Krzykalla J,et al.Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications[J].Blood Adv,2022,6(18):5345-5355.
[40] Wang J X,Jiang B,Li J,et al.Gilteritinib versus salvage chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia:a phase 3,randomized,multicenter,open-label trial in Asia[J].Blood,2021,138(Supplement 1):695.
[41] Roboz G J,DiNardo C D,Stein E M,et al.Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia[J].Blood,2020,135(7):463-471.
[42] Stein E M,DiNardo C D,Pollyea D A,et al.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J].Blood,2017,130(6):722-731.
[43] DiNardo C D,Montesinos P,Schuh A C,et al.Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized,phase 3 IDHentify trial[J].Blood,2021,138(Supplement 1):1243.
[44] Souers A J,Leverson J D,Boghaert E R,et al.ABT-199,a potent and selective BCL-2 inhibitor,achieves antitumor activity while sparing platelets[J].Nat Med,2013,19(2):202-208.
[45] Leverson J D,Sampath D,Souers A J,et al.Found in translation:how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax[J].Cancer Discov,2017,7(12):1376-1393.
[46] 中国临床肿瘤学会白血病专家委员会，马军，王建祥，等.维奈克拉治疗恶性血液病临床应用指导原则(2021年版)[J].白血病.淋巴瘤，2021,30(12):710-718.
[47] Wei A H,Strickland S A Jr,Hou J Z,et al.Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia:results from a phase ib/Ⅱ study[J].J Clin Oncol,2019,37(15):1277-1284.
[48] Aldoss I,Pullarkat V,Stein A S.Venetoclax-containing regimens in acute myeloid leukemia[J].Ther Adv Hematol,2021,12:2040620720986646.
[49] Marvin-Peek J,Savani B N,Olalekan O O,et al.Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia[J].Cancers (Basel),2022,14(3):497.
基本信息:
中图分类号:R733.71
引用信息:
[1]郑金娥,薛维,杜雯,等.急性髓系白血病的精准诊治[J].巴楚医学,2025,8(01):1-11.
基金信息:
浙江省科学技术厅应急攻关项目(2022C03189)
2023-08-14
2023
2023-10-07
2024-10-21
2024
2
2025-03-30
2025-03-30